Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers

Obesity

Volumn 24, Issue 11, 2016, Pages 2278-2288

  Fujioka, Ken ^a   O'Neil, Patrick M ^b   Davies, Melanie ^c   Greenway, Frank ^d   C W Lau, David ^e   Claudius, Birgitte ^f   Skjøth, Trine Vang ^f   Bjørn Jensen, Christine ^f   P H Wilding, John ^g  

^a SCRIPPS CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; PLACEBO; ANTIOBESITY AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; BIOASSAY; BLOOD; BODY MASS; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXERCISE; IMPAIRED GLUCOSE TOLERANCE; MIDDLE AGED; RESPIRATORY SYSTEM; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; BIOMARKERS; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; EXERCISE; FEMALE; HUMANS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; PREDIABETIC STATE; QUALITY OF LIFE; RESPIRATORY SYSTEM; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84993953640     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21629     Document Type: Article

References (30)

1. Golden J. FDA 2007 Draft Guidance for Industry: Developing Products for Weight Management. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. March 28, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM299133.pdf. Accessed 5 May 2016.
2. European Medicines Agency. Guideline on Clinical Evaluation of Medicinal Products used in Weight Control. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170278.pdf. Published 2014 June 26. Accessed 5 May 2016.
3. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-362.
4. Wadden TA, Foster GD, Wang J, et al. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992;56:271S-274S.
5. Stotland SC, Larocque M. Early treatment response as a predictor of ongoing weight loss in obesity treatment. Br J Health Psychol 2005;10:601-614.
6. Handjieva-Darlenska T, Handjiev S, Larsen TM, et al. Initial weight loss on an 800-kcal diet as a predictor of weight loss success after 8 weeks: the Diogenes study. Eur J Clin Nutr 2010;64:994-999.
7. Unick JL, Neiberg RH, Hogan PE, et al.; Look AHEAD Research Group. Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity (Silver Spring) 2015;23:1353-1356.
8. Rissanen A, Lean M, Rössner S, Segal KR, Sjöström L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003;27:103-109.
9. Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond) 2016;40:1369-1375.
10. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006;8:206-213.
11. Smith SR, O'Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014;22:2137-2146.
12. Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract 2010;64:4-11.
13. Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784-793.
14. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373:11-22.
15. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA 2015;314:687-699.
16. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102-111.
17. Maruish ME. User's Manual for the SF-36V2 Health Survey. 3rd ed. Lincoln, RI: Quality Metric; 2011.
18. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249.
19. Eisai Inc. Belviq (Lorcaserin Hydrochloride) Full Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Revised June 2012. Accessed 5 May 2016.
20. Takeda Pharmaceuticals America, Inc. Contrave (Naltrexone HCl and Bupropion HCl) Extended-Release Tablets Full Prescribing Information. http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=eedcee06-8dad-4cf0-910b-06e13004a474. Revised September 2014. Accessed 5 May 2016.
21. Vivus Inc. QSYMIA (Phentermine and Topiramate Extended-Release Capsules, for Oral Use, CIV). Highlights of Prescribing Information. https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf. Revised October 2014. Accessed 5 May 2016.
22. Novo Nordisk Inc. Saxenda® (Liraglutide [rDNA Origin] Injection) Full Prescribing Information. http://www.novo-pi.com/saxenda.pdf. Revised January 2015. Accessed 5 May 2016.
23. European Medicines Agency. Saxenda (Liraglutide 3.0 mg). Summary of Product Characteristics. 2015. http://ec.europa.eu/health/documents/community-register/2015/20150323131125/anx_131125_en.pdf. Accessed 5 May 2016.
24. Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity 2014;22(S2):S1-S410.
25. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012;97:27-42.
26. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251.
27. Ferguson C, David S, Divine L, et al., George Washington University. Obesity Drug Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic Intervention. Available from: http://publichealth.gwu.edu/pdf/obesitydrugmeasures.pdf Published 2012. Accessed 5 May 2016.
28. Crosby RD, Kolotkin R, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004;57:1153-1160.
29. FDA. Liraglutide 3.0 mg for Weight Management, NDA 206-321. Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413318.pdf. Published 11 September 2014. Accessed 5 May 2016.
30. Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes Obes Metab 2016;18:491-499.